Sign In
Buy CMPGY
$32.39
+0.120 (+0.372%)
At Close: Jun 03, 2026
Compass Diversified Declares First Quarter 2025 Distributions on Common and Series A, B and C Preferred Shares
04:10pm, Thursday, 03'rd Apr 2025
WESTPORT, Conn., April 03, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market branded consumer and industrial businesses, a
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
04:05pm, Wednesday, 02'nd Apr 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Lexecon Further Enhances Leading Academic Expertise
07:30am, Wednesday, 02'nd Apr 2025
Twenty Academic Affiliates Have Joined Compass Lexecon in the Past Six Months Affiliates Bring Prior Experience at Government Agencies Including the FTC, FCC and SEC Deep Expertise in a Wide Range of
Compass Diversified Announces Appointment of Matthew Blake as CEO of Arnold Magnetics
08:30am, Tuesday, 01'st Apr 2025
WESTPORT, Conn., April 01, 2025 (GLOBE NEWSWIRE) -- Compass Diversified Holdings (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market branded consumer and industrial busin
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical c
Compass Minerals Announces Cost Cuts to Align With Business Needs
12:05pm, Friday, 28'th Mar 2025
CMP plans to closely examine costs across its operations to uncover further opportunities for cost reductions.
Compass Diversified Preferreds: One Of The Lowest Risk, Very High Yields Today
07:05am, Thursday, 27'th Mar 2025
A rock-solid 7.4x coverage ratio and strong insider alignment make this dividend very low risk. Near 9% yield, upside to par, and qualified dividends for taxable accounts? Yes, please. This preferred
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
06:30am, Wednesday, 26'th Mar 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc
Compass Minerals Announces Cost Structure Reductions to Align With Current Business Needs
04:17pm, Tuesday, 25'th Mar 2025
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today announced measures to reduce selling, general and administration (SG&A) and o
Compass (COMP) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 24'th Mar 2025
Compass (COMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Antitrust and Industrial Organization Expert Matthew Backus Affiliates with Compass Lexecon
07:30am, Thursday, 20'th Mar 2025
WASHINGTON, March 20, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced that Dr. Matthew Backus has affiliated with the firm's Compass Lexecon subsidiary.
Industrial Organization, Platform Economics and AI expert Mehmet Ekmekci Affiliates with Compass Lexecon
07:30am, Tuesday, 18'th Mar 2025
WASHINGTON, March 18, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced Dr. Mehmet Ekmekci has affiliated with the firm's Compass Lexecon subsidiary. Dr. Ekmekci is a Professor
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
06:30am, Tuesday, 18'th Mar 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc
Renowned Markets and Econometrics Expert Professor Ali Hortaçsu Affiliates with Compass Lexecon
07:30am, Friday, 14'th Mar 2025
WASHINGTON, March 14, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced that Dr. Ali Hortaçsu, the William M. Ogden Distinguished Service Professor of Economics at the Univers
Compass considering buying Berkshire Hathaway's real estate brokerage business: WSJ
06:52am, Friday, 14'th Mar 2025
CNBC's Becky Quick reports on the latest news.
